Differential effects of peroxisome proliferator-activated receptor ligands and sulfonylurea plus statin treatment on plasma concentrations of adipokines in type 2 diabetes with dyslipidemia.

[1]  M. Hanefeld,et al.  A long‐term comparison of pioglitazone and gliclazide in patients with Type 2 diabetes mellitus: a randomized, double‐blind, parallel‐group comparison trial , 2005, Diabetic medicine : a journal of the British Diabetic Association.

[2]  W. Yin,et al.  Independent prognostic value of elevated high-sensitivity C-reactive protein in chronic heart failure. , 2004, American heart journal.

[3]  R. Nagai,et al.  Direct reciprocal effects of resistin and adiponectin on vascular endothelial cells: a new insight into adipocytokine-endothelial cell interactions. , 2004, Biochemical and biophysical research communications.

[4]  J. Plutzky.  PPARs as Therapeutic Targets: Reverse Cardiology? , 2003, Science.

[5]  S. Verma,et al.  Resistin Promotes Endothelial Cell Activation: Further Evidence of Adipokine-Endothelial Interaction , 2003, Circulation.

[6]  Shing‐Jong Lin,et al.  The prognostic value of circulating soluble cell adhesion molecules in patients with chronic congestive heart failure , 2003, European journal of heart failure.

[7]  Peter Olson,et al.  Printed in U.S.A. Copyright © 2003 by The Endocrine Society doi: 10.1210/en.2003-0288 Minireview: Lipid Metabolism, Metabolic Diseases, and , 2022 .

[8]  J. Bełtowski.  Adiponectin and resistin--new hormones of white adipose tissue. , 2003, Medical science monitor : international medical journal of experimental and clinical research.

[9]  P. Froguel,et al.  Globular Adiponectin Protected ob/ob Mice from Diabetes and ApoE-deficient Mice from Atherosclerosis* , 2003, The Journal of Biological Chemistry.

[10]  J. Mckenney,et al.  National Cholesterol Education Program Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) , 2002 .

[11]  Q. Zhong,et al.  Endothelin-1 inhibits resistin secretion in 3T3-L1 adipocytes. , 2002, Biochemical and biophysical research communications.

[12]  Philippe Froguel,et al.  Disruption of Adiponectin Causes Insulin Resistance and Neointimal Formation* , 2002, The Journal of Biological Chemistry.

[13]  A. Shuldiner,et al.  Resistin, obesity, and insulin resistance--the emerging role of the adipocyte as an endocrine organ. , 2001, The New England journal of medicine.

[14]  M. Matsuda,et al.  PPARgamma ligands increase expression and plasma concentrations of adiponectin, an adipose-derived protein. , 2001, Diabetes.

[15]  Y. Terauchi,et al.  The fat-derived hormone adiponectin reverses insulin resistance associated with both lipoatrophy and obesity , 2001, Nature Medicine.

[16]  T. Willson,et al.  Adipose Tissue Resistin Expression Is Severely Suppressed in Obesity and Stimulated by Peroxisome Proliferator-activated Receptor γ Agonists* , 2001, The Journal of Biological Chemistry.

[17]  Paul M. Ridker,et al.  Measurement of C-reactive protein for the targeting of statin therapy in the primary prevention of acute coronary events. , 2001, The New England journal of medicine.

[18]  T. Funahashi,et al.  The Journal of Clinical Endocrinology & Metabolism Printed in U.S.A. Copyright © 2001 by The Endocrine Society Hypoadiponectinemia in Obesity and Type 2 Diabetes: Close Association with Insulin Resistance , 2022 .

[19]  NoriyukiOuchi,et al.  Adipocyte-Derived Plasma Protein, Adiponectin, Suppresses Lipid Accumulation and Class A Scavenger Receptor Expression in Human Monocyte-Derived Macrophages , 2001 .

[20]  M. Lazar,et al.  The hormone resistin links obesity to diabetes , 2001, Nature.

[21]  大内 乗有.  Novel modulator for endothelial adhesion molecules : Adipocyte-derived plasma protein adiponectin , 2001 .

[22]  S. Kihara,et al.  Adiponectin, an Adipocyte-Derived Plasma Protein, Inhibits Endothelial NF-&kgr;B Signaling Through a cAMP-Dependent Pathway , 2000, Circulation.

[23]  J. Flier,et al.  Obesity and insulin resistance. , 2000, The Journal of clinical investigation.

[24]  T Nakamura,et al.  Plasma concentrations of a novel, adipose-specific protein, adiponectin, in type 2 diabetic patients. , 2000, Arteriosclerosis, thrombosis, and vascular biology.

[25]  D. Bishop-Bailey.  Peroxisome proliferator‐activated receptors in the cardiovascular system , 2000, British journal of pharmacology.

[26]  E. Ravussin,et al.  Decreased Expression Of apM1 in Omental and Subcutaneous Adipose Tissue of Humans With Type 2 Diabetes , 2000, International journal of experimental diabetes research.

[27]  R. Ross.  Atherosclerosis is an inflammatory disease , 1999 .

[28]  W. Wahli,et al.  Peroxisome proliferator-activated receptors: nuclear control of metabolism. , 1999, Endocrine reviews.

[29]  S. Kihara,et al.  Role of adipocytokines on the pathogenesis of atherosclerosis in visceral obesity. , 1999, Internal medicine.

[30]  M. A. Crook,et al.  Is Type II diabetes mellitus a disease of the innate immune system? , 1998, Diabetologia.

[31]  Christopher K. Glass,et al.  The peroxisome proliferator-activated receptor-γ is a negative regulator of macrophage activation , 1998, Nature.

[32]  Richard Barnett,et al.  Diabetes mellitus. , 1993, The Medical journal of Australia.